Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Monopar Therapeutics Inc. (MNPR) filed an 8-K to disclose the results of its 17 June 2025 Annual Meeting of Stockholders. Of the 6,115,214 shares entitled to vote, 82.6% (5,048,394) were represented in person or by proxy.
- Director elections: All six nominees—including CEO Chandler D. Robinson and Chair Christopher M. Starr—were elected. Support ranged from 78.7% to 99.9% of votes cast, with 655,826 broker non-votes recorded for each nominee.
- Say-on-pay: Executive compensation was approved with 4,382,795 votes for (99.8%), 2,933 against, and 6,840 abstentions.
- Say-on-pay frequency: Shareholders selected an annual advisory vote, receiving 4,383,765 votes, dwarfing biennial (1,247) and triennial (1,212) options.
- Auditor ratification: BPM LLP was ratified as independent accountant for FY-2025 with 5,044,817 votes for (99.9%).
No other matters were submitted. The outcome signals continued shareholder support for current governance, compensation practices, and audit oversight. No immediate financial impact or strategic change was disclosed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
How many Monopar Therapeutics (MNPR) SEC filings are available on StockTitan?
StockTitan tracks 73 SEC filings for Monopar Therapeutics (MNPR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.
When was the most recent SEC filing for Monopar Therapeutics (MNPR)?
The most recent SEC filing for Monopar Therapeutics (MNPR) was filed on July 2, 2025.